EXEL
NASDAQ
$55.53
Exelixis Inc (EXEL)
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Sector:
Healthcare
Industry:
Biotechnology
Hold
Target: $50.93 (-8.28%)
Market Cap
$14B
PEG Ratio
0.45
EPS 5Y CAGR
+72.24%
FCF 5Y CAGR
+43.37%
Price Chart
Valuation
Market Cap$14B
P/E17.54
Forward P/E17.70
PEG0.45
P/S5.89
P/B7.21
Profitability
Total Revenue (TTM)$2.38B
Gross Profit (TTM)$2.29B
EBITDA$965M
Profit Margin34.5%
Operating Margin41.2%
EPS$3.17
Financial Health
Free Cash Flow Yield6.51%
Growth & Risk
EPS 5Y CAGR+72.24%
Revenue 5Y CAGR+18.17%
FCF 5Y CAGR+43.37%
Beta (5Y)0.52
Sharpe Ratio0.65